
Index

- A**
- AADC. *See* Aromatic L–amino acid decarboxylase
- AAV. *See* Adeno–associated virus
- Abbvie, 91, 192
- Abecma, 125
- Abraham Lincoln’s DNA and Other Adventures in Genetics*, 131
- ACA. *See* Affordable Care Act
- Acquired immunodeficiency syndrome (AIDS), xxiv, 6, 24–27, 41
- Acute hepatic porphyria (AHP), 86
- Adakveo, 143
- Adderall, 89
- Adeno–associated virus (AAV), 129–131, 133, 135–136, 196
- Adenovirus vector, 130
- ADHD. *See* Attention deficit hyperactivity disorder
- Adrenoleukodystrophy (ALD), 123, 125
- Aducanumab, 76
- Afeyan, Noubar, 126
- Affordability, orphan drugs
- drug development costs, 184–187
 - one–time treatments, 194–196
 - overview, 9–10, 183–184
 - patient resources, 187–191
 - societal considerations, 191–194
- Affordable Care Act (ACA), 9, 38, 187, 202
- AHF. *See* Antihemophilic factor
- AHP. *See* Acute hepatic porphyria
- AIDS. *See* Acquired immunodeficiency syndrome
- Alam, John, 79
- Albers, Jeff, 51
- ALD. *See* Adrenoleukodystrophy
- Aldrich, Rich, 79, 162
- Aldurazyme, 70–71, 194
- Alexion, 76–78, 160
- Alizé Pharma, 173–174
- Alliance for Regenerative Medicine (ARM), 195
- Allison, Jim, 121
- Alnylam Pharmaceuticals, 73, 83–87, 132, 162
- Alpha–1 antitrypsin deficiency, 83, 104
- ALS. *See* Amyotrophic lateral sclerosis
- Altschuler, Steve, 170
- Alzheimer’s disease, xvii, 3–4, 76, 176
- Amgen, xxiv, 35, 37, 69, 143
- Amicus, 87–88
- Amyloidosis transthyretin (ATTR), 69, 86
- Amyotrophic lateral sclerosis (ALS), xiii, 161, 198, 206
- Anand, Geeta, 45
- Andersen, Terkel, 206
- Angelman syndrome, 161
- The Antidote*, 79
- Antihemophilic factor (AHF), 25
- Antisense RNA, 75, 210
- Antithrombin III (AT3), 97–98, 102–104
- ARM. *See* Alliance for Regenerative Medicine
- Aromatic L–amino acid decarboxylase (AADC), 133
- Aspinall, Mara, 51
- Astellas Pharmaceuticals, 172
- AstraZeneca, 78, 128
- Astrue, Michael, 6, 89, 162
- AT3. *See* Antithrombin III
- ATryn, 103–104
- Attention deficit hyperactivity disorder (ADHD), 89
- ATTR. *See* Amyloidosis transthyretin
- Aubourg, Patrick, 123

Audentes, 171–172
Aurora Biosciences, 80
Auspitz, Ben, 149
Avexis, 170–171
Avigen, 133
Avonex, 74

B

Bain and Company, xxv, 25
Bamforth, Mark, 108, 169
Bankiewicz, Krys, 132
Bartel, David, 84
Barton, Norm, 17
Bartsch, Olaf, 58
Batten's disease, 71, 210
Baxalta, 91–92
Baxter, 24–28, 39, 91, 97, 122, 145, 162
Baxter Travenol, 19–20, 32
Beall, Bob, 80–82
Béchon, Christian, 104
Bell, Leonard, 76
Bennett, Jean, 170
Berman, Brian, 33–35
Bernstein, Brad, 138
Bespoke Gene Therapy Consortium (BGTC), 196
Betaseron, 74
BGTC. *See* Bespoke Gene Therapy Consortium
Biden, Joe, 202
Bienaimé, Jean-Jacques, 30, 71
The Billion Dollar Molecule, 79
BIO. *See* Biotechnology Innovation Organization
BioCentury, 35
Biogen, xxiv, 16, 35, 72–78, 96, 128, 162, 171
BioMarin, 29–30, 70, 162
BioMatrix, 51
BioSurface Technology, 50
Biotechnology Innovation Organization (BIO), 87, 189–190
BIO Ventures for Global Health (BVGH), 204–205
Bioverativ, 75, 162
Bird, Adrian, 139
Blackrock, 205
Blair, Henry, 19
Blair, Tony, 15

bluebird, 124–126, 194
Boger, Josh, 78–79, 81
Boice, Nicole, 197
Bonney, Mike, 162
Borgignon, Claudio, 146
Boriero, Massimo, 58
Bosley, Katrine, 162
The Boy in the Plastic Bubble, 146
Boyce, Nicole, 206
Boyer, Herbert, 14, 16, 121
Brady, Roscoe, 16–19, 31, 33, 35–36
Brammer Bio, 169
Broad Institute, 15, 138
Burns, Jim, 51
Butler, John, 51
BVGH. *See* BIO Ventures for Global Health

C

Califf, Robert, 168, 202
California Institute of Regenerative Medicine (CIRM), 149
Campath, 50
Campbell, Bradley, 88
CANbridge, 158–160
CARD. *See* China Alliance for Rare Diseases
Career Imprints: Creating Leaders across an Industry, xxvi
Carpenter, Bob, 39, 96–97, 112
CAR-T cell, 124–125
Carticel, 50
Cartier, Nathalie, 123
CBER. *See* Center for Biologics Evaluation and Research
CCF. *See* Chinese Charitable Federation
CDER. *See* Center for Drug Evaluation and Research
Cedilla Therapeutics, 162
Celgene, 69, 124
Center for Biologics Evaluation and Research (CBER), 167, 169
Center for Drug Evaluation and Research (CDER), 167
Centronuclear myopathy (CNM), 174
Ceredase, 36–40, 57, 59–61, 63
Cerezyme, 39–40, 46–47, 61, 63, 66, 97, 107–108, 156–157
CF. *See* Cystic fibrosis
CFE. *See* Cystic Fibrosis Foundation

- Chagas disease, 64
Chen, Y.T., 44
Cheng, Seng, 136
Chéreau, Fred, 51, 173
Cheresky, Marcelo, 64, 159
China
 biotechnology overview, 4–5, 127,
 155–156
 CANbridge, 158–160
 Genzyme interactions, 156–158
China Alliance for Rare Diseases (CARD), 159
Chinese Charitable Federation (CCF), 157
Chinoporos, Constantine, 110
CHMP. *See* Committee for Medicinal
 Products for Human Use
Choudhury, Prithwiraj, 65
Christensen, Gustav, 91
Chronic lymphocytic leukemia (CLL), 50
Cinryze, 90
CIRM. *See* California Institute of
 Regenerative Medicine
Clementia, 174
Clinical trials, costs, 185
Clinton, Bill, 15
CLL. *See* Chronic lymphocytic leukemia
CNM. *See* Centronuclear myopathy
The Code Breaker, 206
Coenraads, Monica, 139–140
Cohen, Stanley, 14
Coles, Tony, 162
Collier, Duke, 37
Collins, Francis, 15
Collins, Michael, 84
Committee for Medicinal Products for
 Human Use (CHMP), 152
*Conscience and Courage: How Henri Termeer
 Built a Biotech Giant and Pioneered the
 Rare Disease Industry*, xxvi, 31, 33
Cooney, Charlie, 31, 97
Cornu, François, 58–59
Corr, Bill, xx
Coughlin, Bob, 197
COVID-19, xvii, 84, 97, 126, 155, 168, 203
Cox, Geoff, 102
Cox, Gerry, 159
Cox, John, 162, 204
Cox, Tim, 39, 60
Creating Hope Act, 7
Crick, Francis, 14, 137
Crohn's disease, 153
Crowley, John, 45, 87–88
Crowley, Megan, 45
Crowley, Patrick, 45
Creutzfeldt–Jacob disease, 28
Csimma, Zoltan, 49
Cubist Pharmaceuticals, 162
Cure Duchenne, 206
*The Cure: How a Father Raised \$100
 Million—and Bucked the Medical
 Establishment—In a Quest to Save His
 Children*, 45
Cure Rare Disease, 210
CXCR4, 174
Cystic fibrosis (CF), xiii, xv, xviii, 3, 47–48, 55, 69,
 80–83, 101, 161
Cystic Fibrosis Foundation (CFF), 47,
 80–83, 206
- D**
- Dant, Jeanne, 70
Dant, Mark, 70
Dant, Ryan, 70–72
Daraprim, 186
DaSilva, Isabel Aznarez, 175
Davidson, Dave, 124
de Duve, Christian, 16–17
de la Tourette, George, xi
Denali Therapeutics, 126
Developing countries, orphan drug access,
 203–205
DMD. *See* Duchenne muscular dystrophy
Doudna, Jennifer, 206
Douglas, Richard, 49
Dravet syndrome, 161, 175
Duchenne muscular dystrophy (DMD), xv, 3,
 69, 163–167, 198, 202, 210
Dunoyer, Marc, 78
Dunsire, Deborah, 162
DUX-4, 140
Dyax, 91
Dynacure, 174
Dystrophin, 163, 166–167
Dzau, Victor, 112
- E**
- Ebert, Karl, 98
Ebola, 8

Echelard, Yann, 103
Eculizumab, 77
Editas Medicine, 126, 162
Elaprase, 90
el-Beshlawy, Amal, 66
El-Bialy, Mehat, 66
Eli Lilly, 90, 120, 132
Ely, Robin, 34–35
EMA. *See* European Medicines Agency
ENCODE, 137
Enyedy, Mark, 51
Epogen, 37
EPPOSI. *See* European Platform for Patients
Organizations, Science and Industry
Erythropoietin, 89
Escape Bio, 175
Escherichia coli, 8
ESG investing, 205–206
Esiason, Boomer, xiii
Eteplirsen, 164–169, 201
Eugenics, 15
EURODIS, 55–56, 67, 197, 206
EuropaBio, 55
European Medicines Agency (EMA), 59,
61–62, 125, 147, 150, 152, 168
European Platform for Patients
Organizations, Science and Industry
(EPPOSI), 55–56, 195
Everett, Wendy, 197
EveryLife Foundation for Rare Diseases,
7, 145
Extraordinary Measures, 45

F

Fabrazyme, 42, 47, 61, 107–108
Fabry disease, 3, 17, 40, 42–43, 62, 66–67, 87
Facioscapulothoracic dystrophy (FSTD), xiv,
140–141
Factor VII, 104–105
Factor VIII, 21, 23–28, 30, 39, 89, 104
Factor IX, 21, 23, 104
FDA. *See* Food and Drug Administration
Feldbaum, Carl, 189–190
Fibrodysplasia ossificans progressiva
(FOP), 174
Fierce Biotech, 132, 138, 149
Finkel, Marion, xx
FioCruz, 64

Firazyr, 90–91
Fire, Andrew, 83
Fischer, Alain, 146
Flagship, 126–127, 175, 211
Fleming, Dave, 156–157
Flotte, Terry, 84
Food and Drug Administration (FDA)
Abecma approval, 125
Aldurazyme approval, 70–71
Ceredase approval, 36
Fabrazyme approval, 42
Lumizyme approval, 46
Onpatro approval, 86
orphan drug approval, 2, 6
Patient-Focused Drug Development, 199
Sarepta interactions, 164–168
transfusion risk estimates for AIDS, 26
Food, Drug and Cosmetic Act, 6
FOP. *See* Fibrodysplasia ossificans
progressiva
Forbion, 127
Formela, Jean-François, 126
F-Prime Capital, 148–149
Fragile X syndrome (FXS), 140
Frates, Pete, xiii, 198
FRD. *See* Frontotemporal dementia
Friedman, John, 122
Frontotemporal dementia (FTD), 153
FSTD. *See* Facio-scapular-humoral
dystrophy
FTX-6058, 144
Fulcrum Therapeutics, 138–144
Furbish, Scott, 17
Furlong, Pat, 165–166, 198
FXS. *See* Fragile X syndrome

G

Galafold, 87–88
Galakatos, Nick, 86
Gao, Guangping, 131, 160
Gaspar, Bobby, 148, 150
Gates Foundation, 111, 204
Gaucher disease, 3, 17, 31, 33–40, 43, 47,
55, 60–64, 66–67, 108–109, 145,
156, 159
Gaucher, Philippe, xiii, 17
Gavin, Bill, 104
GBT. *See* Global Blood Therapeutics

- Gelsinger, Jessie, 130, 147
GelTex Pharmaceuticals, 49
Gene editing, 209
Genentech, xxiv, 16, 121
Generation Bio, 173
Genetics Institute (GI), 27–28, 89
Genetix Pharmaceuticals, 121–126, 129
Genzyme, xxvi, 20, 31, 33–40, 42–52, 55, 57–67, 69, 87–88, 97–99, 107–115, 119, 123, 128, 145, 156–157, 162–163
Genzyme Transgenics Corporation (GTC), 99–105
Gerety, Bob, 162
GI. *See* Genetics Institute
Gilbert, Walter, 72
Gilead, 69, 79
Givlaari, 86
GlaxoSmithKline (GSK), 87, 130, 140, 147, 149
Glaxo Wellcome, 79
Global Blood Therapeutics (GBT), 143–144
Global Genes, 7, 197, 206
Glucksmann, Alexandra, 162
Goater, Jeff, 132
Goldberg, Mark, 159
Gordon, Katie, 96
Gottesdiener, Keith, 175
Gottlieb, Scott, 169
Gould, Robert, 138
Graham, Bill, 19, 32, 39, 97
Gray, Mary Ann, 91
The Great American Drug Deal: A New Prescription for Innovative and Affordable Medicines, xxvi, 192
Green, Michael, 138
Greene, Barry, 86
Greenwood, Jim, 71, 189–190
Gregoire, Sylvie, 90
Gregory, Rich, 159
Groet, Suzanne, 159
Groft, Steve, 7
GSK. *See* GlaxoSmithKline
GTC. *See* Genzyme Transgenics Corporation
- H**
- HA. *See* Hyaluronic acid
HAE. *See* Hereditary angioedema
Haffner, Marlene, 41
Hassan, Glenn, 159
Hastings, Paul, 57–58
Hatch, Orrin, xxii
Hawkins, John, xxvi, 31, 33, 162
Health Technology Assessment (HTA), 190–191
Heffernan, Jack, 49
Hematopoietic stem cell (HSC), 146, 153
Hemlibra, 29, 92, 204
Hemophilia, xv, 3, 20–29, 71–72, 75, 104–105, 204
Hempel, Chris, 174
Hempel, Hugh, 174
Hepatitis, 24, 26, 79–80
Hereditary angioedema (HAE), 69, 90–91
Hesslein, Bob, 110
Higgins, Michael, 134
Higgins, Monica, xxvi, 162
High, Kathy, 170
HIV. *See* Human immunodeficiency virus
Hoffman, Steve, 122
Homology Medicines, 162
Horgan, Rich, 210
Horowitz, Mia, 39
Howe, John, 156–157
HSC. *See* Hematopoietic stem cell
HTA. *See* Health Technology Assessment
Human Genome Project, 137
Human immunodeficiency virus (HIV), 23–26, 28, 79, 101
Humira, 101, 192–194
huntingtin, 135
Huntington's disease, xv, 135–136
Hyaluronic acid (HA), 50
Hydroxyurea, 142
Hyland Laboratories, 23
- I**
- Icahn, Carl, 110
Ice Bucket Challenge, xiii, 198
ICER. *See* Institute for Clinical and Economic Review
IDEC Pharmaceuticals, 75
Iduronidase, 70
IG. *See* Integrated Genetics
Illex Oncology, 50
Immunologic, 162
Incerti, Carlo, 61

260 *Index*

Incivek, 79
The Innovators, xxvi
Institute for Clinical and Economic Review
(ICER), 82, 202
Institute for Life-Changing Medicines, 200
Insulin, 16
Integrated Genetics (IG), 39–40, 49,
96–98
International Pompe Association,
57, 206
Intron A, 72
In vitro fertilization (IVF), 210
Ionis Pharmaceuticals, 75
Ipsen, 174
Isaacson, Walter, xxvi, 206
IVF. *See* In vitro fertilization

J

Jaenisch, Rudolf, 138
Jerini AG, 90
Johnson, Malcolm, 58
Journey, 22

K

Kakkis, Emil, 69–71, 162
Kalydeco, 81–82
Kanuma, 78
Karen, xviii
Kay, Mark, 132, 172
Kaye, Ed, 164, 166, 175
Kefauver–Harris amendments, Food, Drug
and Cosmetic Act, 6
Kennedy, Ted, xix, 3
Kennedy Shriver, Eunice, xviii
Kent, Alastair, 56
Kessler, David, 36
Khanna, Tarun, 65
Kids v Cancer, 7
Kilillea, Marie, xviii
Kinsella, Kevin, 79
Klugman, Jack, xx–xxii
Kohn, Donald, 149
Kolchinsky, Peter, xxvi, 189, 192
Kolodny, Ed, 17
Kowtunik, Walt, 138
Kraimer, Adrian, 175
Kunkel, Lou, 163

L

Lander, Eric, 15, 121
Langer, Bob, 175
Lasagna, Louis, 6
LDL. *See* Low-density lipoprotein
LeBoulch, Philippe, 121
LeCam, Yann, 55
Lee, Jeannie, 138
Leiden, Jeff, 81
Lemtrada, 113
Leschly, Nick, 124
Levin, Mark, 119–120, 130–132, 138
Levy, Alberto, 63
Lewis, Jerry, xiii, xviii
LFB Group, 104
Libmeldy, 152
Lipitor, 14
Littlechild, John, 19
Lodish, Harvey, 31
LogicBio, 160, 172
London, Irving, 121
*Looking the Tiger in the Eye: Confronting the
Nuclear Threat*, 189
Lorenzo's Oil, 123
Losmapimod, 140
Love, Ted, 143
Low-density lipoprotein (LDL), 85
Lumizyme, 46–47
Luxturna, 170
Lysosomal acid lipase deficiency, 78

M

Mad cow disease, 28
Maderis, Gail, 51
Madison, Greg, 51
Malvilio, Fulvio, 146
Maniatis, Tom, 27
Marfan's syndrome, 15
Marganore, John, 84–86, 162
Marks, Peter, 169, 210
Marrazzo, Jeff, 170
Martin, Craig, 197, 206
MassBio, 197
Massie, Robert, 22–23
Massie, Suzanne, 22
MC4R, 175
McDonough, Geoffrey, 51, 173, 204

- McIntosh, David, 6
McKee, Blaine, 51
McLachlan, Dave, 49
McLaughlin, James, 130
McMurry–Heath, Michelle, 190
McNeil Laboratories, xii
McPhee, John, 161
Meade, Harry, 95–96, 98, 103
Meeker, David, 51, 114, 175
Meijer, Dick, 58
Mello, Craig, 83
Mendel, Jerry, 170
Merck, 85
Merieux, Alain, 36
Merrifield, Ann, 51
Mersana Therapeutics, 162
Metachromic leukodystrophy (MLD), xiv, 69, 150–152
Methylmalonic acidemia (MMA), 161, 173
Metzenbaum, Howard, 38
Meyers, Abbey, xi–xiii, xx–xxi, 37, 67, 197, 206, 212
Meyers, David, xi–xii, xxi
Meyers, Jerry, xi–xiii, xxi
Meyers, Rachel, 86
Milano, Vin, 90
Milk, transgenic goat production of pharmaceuticals, 95–105
Millendo Therapeutics, 174
Millennium Pharmaceuticals, 120, 162
Milstein, George, 124
Mintz, Beatrice, 96
Mistry, Pram, 17
MLD. *See* Metachromic leukodystrophy
MMA. *See* Methylmalonic acidemia
Moderna, 97, 126
MolMed, 147
Mondale, Walter, 63
More, Ginger, 19
Moreno, Jose, 104
Moscicki, Rich, 34
Mott, Dave, 126
MPS. *See* Mucopolysaccharidosis
MS. *See* Multiple sclerosis
Mucopolysaccharidosis (MPS), xiv, 66–67, 69–72, 148, 159, 194
Mueller, Peter, 79
Mulder, Geert–Jan, 122
Mullen, Jim, 75
Multiple sclerosis (MS), 50, 72–74, 101, 113
Murcko, Mark, 79
Muscular Dystrophy Association, 167
Myasthenia gravis, 101
Myozyme, 46–47, 62, 65, 108
- N**
- Nader, François, 91
Naldini, Luigi, 146
Narasimhan, Vas, 171
National Center for Advancing Translational Sciences (NCATS), 7
National Gaucher Foundation (NGF), 34, 38, 206
National Hemophilia Foundation (NHF), 26
National Institute for Health and Clinical Excellence (NICE), 60, 152, 191
National Organization for Rare Disorders (NORD), xxiii, 37, 41, 67, 197, 206
NBS. *See* Newborn screening
NCATS. *See* National Center for Advancing Translational Sciences
Neglected tropical diseases (NTDs), 7
NEHI, 197
Nelsen, Bob, 126
Neufeld, Liz, 71
Neurocrine Biosciences, 134
New England Enzyme Center, 19
Newborn screening (NBS), 201
NGF. *See* National Gaucher Foundation
NHF. *See* National Hemophilia Foundation
NICE. *See* National Institute for Health and Clinical Excellence
Nicholas and Alexandra, 22
Nicholas II, 21
Niemann–Pick disease, 17, 174, 176
N of 1, 34–35, 209–210
No Patient Left Behind, 188
NORD. *See* National Organization for Rare Disorders
Novartis, 85, 136, 171, 194, 203
Novazyme, 44–45, 87
Noyes, Tim, 51
NPS Pharma, 91
NTDs. *See* Neglected tropical diseases

262 *Index*

Nuredis, 176
Nuvelo, 143

O

ODA. *See* Orphan Drug Act
ODD. *See* Orphan Drug Designation
Office of Rare Disease Research, 7
Office of Technology Assessment (OTA),
37–38
Ogier, Walter, 122
Onpattro, 86–87
Onyx Pharmaceuticals, 143, 162
Operation Warp Speed, 168
Orbimed, 171–172
Orchard Therapeutics, 148–149, 152–153
Orkambi, 82, 191
Ornithine transcarbamylase deficiency, 130
Orphan Drug Act (ODA), xviii–xviii,
xx–xxiii, 2–4, 31, 38, 41, 56, 74, 145,
183, 196, 200
Orphan Drug Designation (ODD), 41, 161
Orphan Drugs: A Global Crusade, xxvii
Orphan Drugs and Rare Diseases, xxvii
*Orphan: The Quest to Save Children with Rare
Genetic Disorders*, xv, xxvi, 13–14, 21, 131
Osteoporosis, 91
OTA. *See* Office of Technology Assessment
OvaScience, 162
Ovid Therapeutics, 175
Oxbryta, 143
Oxlumo, 86

P

Papadopoulos, Stelios, 51, 75, 99
PAPs. *See* Patient assistance programs
Parent Project Muscular Dystrophy, 165, 206
Parkinson's disease, xvii, 132–134, 176
Paroxysmal nocturnal hemoglobinuria
(PNH), 3, 69, 76–78, 160
Pasteur Merieux, 36
Pasteur, Alex, 149
Patent thicket, 192
Patient assistance programs (PAPs), 203
Patient-Focused Drug Development
(PFDD), 199
Patrick, Deval, 32, 196, 197

Patterson, Matt, 171–172
Paul, Steve, 132
Personalized medicine, 209–210
PFDD. *See* Patient-Focused Drug
Development
Pfizer, 30, 136
PGT. *See* Preconception genetic testing
PH1. *See* Primary hyperoxaluria type 1
Pharming, 44, 96
Phelps, Greg, 38
Phenylketonuria (PKU), 3, 15, 69, 71, 201
Pierce, Glenn, 204
PKD. *See* Polycystic kidney disease
PKU. *See* Phenylketonuria
Plump, Andy, 128
PNH. *See* Paroxysmal nocturnal
hemoglobinuria
Policy innovation, importance in orphan
drug development, 179–180
Pollack, Axel, 122
Polycystic kidney disease (PKD), xv
Pompe disease, 43–47, 56–57, 62, 87–88, 96,
107–108
Pompe, Johannes, 43
Poole, Sandra, 108
Poortman, Ysbrand, 56
Possible Project, 120
PPL Therapeutics, 96, 100
Prader-Willi syndrome (PWS), 173
Preconception genetic testing (PGT), 211
Primary hyperoxaluria type 1 (PH1), 86
Priority review voucher (PRV), 6–7, 199–200
Pritchard, Amanda, 152
Progressive supranuclear palsy, 161
Project HOPE, 156–157
Protopapas, Anna, 162
PRV. *See* Priority review voucher
Ptashne, Mark, 27
PWS. *See* Prader-Willi syndrome

Q

Qasim, Waseem, 148
Queen Victoria, 21

R

Raab, Mike, 51
Ragan, Paula, 51, 174

- Raptor Pharmaceuticals, 176
Rare Disease Day, 5, 56, 67
RARE Impact Award, 206
Rasputin, 21
Rathmann, George, 143
Ravina, Bernard, 132
RDLP. *See* Research and Development Limited Partnership
Reagan, Nancy, xxii–xxiii
Reagan, Ronald, xxii–xxiii, 3
Recombinate, 28
Redux–4 trial, 141
Regeneron, 69
Reilly, Phil, xv, xxvi, 13–15, 21, 25, 130–132, 138
Reinberg, Danny, 138
Relapse–remitting multiple sclerosis (RRMS), 3, 74
Renagel, 49, 51, 61
Replagal, 42–43, 61
Research and Development Limited Partnership (RDLP), 48
Rett syndrome, xv, 138–140
Rett Syndrome Research Trust (RSRT), 139
Reuser, Arnold, 44
Rhythm Pharmaceuticals, 175
Ridley, David, 6
RNA interference, 83–87
Roberts, Bruce, 96
Roche, 16, 29, 170, 204
Romanov, Alexsei, 21
Romney, Mitt, xxv, 197
Roslin Institute, 100
Rothera, Mark, 149
Royo, Fernando, 58
RPE65, 170
RRMS. *See* Relapse–remitting multiple sclerosis
RSRT. *See* Rett Syndrome Research Trust
Russell, Angus, 90
Ryan Foundation, 70
- S**
- Sah, Dinah, 86, 132
Sahney, Sandeep, 65
Sandrock, Al, 74, 136
Sangamo, 30
Sanger, Frederick, 14
Sangstat, 49–50
Sanofi, 111–115, 124, 128, 133–134, 156–158
Sarepta Therapeutics, 163–167, 201
Sato, Vicki, 79, 162
Scangos, George, 75, 204
SCD. *See* Sickle cell disease
Schering–Plough, 72
Schikan, Hans, 57
Schimmel, Paul, 84
Schmergel, Gabriel, 27–28
Schneider–Mergener, Jens, 90
Schoneveld van der Linde, Maryze, 56–57
SCID. *See* Severe combined immunodeficiency
Secor, Alicia, 51
Seligman, Muriel, xix
Seprafilm, 50
Sevenfact, 104–105
Severe combined immunodeficiency (SCID), 146–153
Shapiro, Arthur, xii
Sharp, Phil, 72–73, 84
Sherblom, Jim, 49
Shire Pharmaceuticals, 87, 89–92, 128
Shkreli, Martin, 186–187
Sickle cell disease (SCD), xv, 3, 15, 83, 121, 123, 141–144
Sigilon Therapeutics, 175
Silverstein, Jonathan, 171
Simonian, Nancy, 162
Sirna Therapeutics, 85
Slanetz, Alfred, 122
SMA. *See* Spinal muscular atrophy
Smith, Alan, 96
Smith, Cees, 56
Smith, Julie Anne, 51, 175–176
Smith, Sandy, 57
Smith, Tom, 99
Snyder, Richard, 169
Snyder, Sherry, 19
Soliris, 77–78
Solvadi, 79–80
A Song in the Night: A Memoir of Resilience, 23
Soteropoulos, Paula, 51
Spark Therapeutics, 29, 170
Special Olympics, xviii
Specter, Arlen, 190

264 *Index*

Spezzi, Andrea, 149
Spinal muscular atrophy (SMA), 69, 72, 75,
170–171, 194, 203
Spinocerebellar ataxia, 161
Spinraza, 75, 171, 175
Squinto, Stephen, 76
Stahel, Rolf, 89
Starr, Kevin, 120
Stoke Therapeutics, 175
Stölzle, Ute, 58, 60
Strimvelis, 147, 149–150
Stuart, Bryan, 144
Suhr, Dean, 151
Suhr, Lindy, 151
Suhr, Teryn, 151
Sulston, John, 15
Swanson, Bob, 16, 121
Symdeko, 82
Syntonix Pharmaceuticals, 75
Synvisc, 51
Syros Pharmaceuticals, 162

T

Tagamet, 13
Takeda, 66, 92, 120, 128
Tambuyzer, Erik, 55
Tecfidera, 74
Telethon Institute for Gene Therapy (TIGET),
146–147
Tepper, Bob, 120
Termeer, Belinda, 114
Termeer, Henri, 20, 27, 31–35, 38–39, 49, 51–
52, 65, 87–88, 98–99, 102, 110, 112–
114, 145
Thalassemia, 15, 83, 121, 123–124, 194
Thalidomide, 6
The Medicines Company (TMC), 85
Thermo Fisher, 169
Third Rock Ventures (TRV), 119–121,
123–124, 126, 128–130, 132, 138,
143, 210
Thomas, Frank, 149
Thrasher, Adrian, 148
Thymoglobulin, 49–50
Thyrogen, 49, 61
Tierney, Tomye, 156–157
TIGET. *See* Telethon Institute for Gene
Therapy

TKT. *See* Transkaryotic Therapies
TMC. *See* The Medicines Company
Tobin, Jim, 73
Tourette's syndrome, xi–xiii
Transkaryotic Therapies (TKT), 42–44, 61–
62, 89–90, 162
Transthyretin amyloidosis. *See* Amyloidosis
transthyretin
Travenol, 19, 32
TRV. *See* Third Rock Ventures
Tung, Roger, 162
Turenne, Andre, 134
Turing Pharmaceuticals, 186
Turner, Frederic, 59
Tuschl, Tom, 84
21st Century Cures Act, 7
Tysabri, 74
Tzianabos, Arthur, 162

U

Ultragenyx, 162
Ultra-orphan diseases, 93, 144–145, 178–
179, 195–196, 199–200
Usdin, Steve, 35

V

Vaishnav, Akshay, 86
Values, importance in orphan drug
development, 177–179
van der Ploeg, Ans, 44
van Heek, Christi, 38
van Heek, Jan, 38, 57
van Rooijen, Stéphane, 51, 174
Varmus, Harold, 111
Vertex, 78–83, 162, 191
Viehbacher, Chris, 111–114
Vincent, Jim, 73
ViroPharma, 90–91
Vivaldi, Rogerio, 51, 63, 175
Vos, Alexander, 51
Vounatsos, Michel, 75
Voyager Therapeutics, 131–136, 138

W

Walsh, Jeff, 124
Warren, Earl, 3

Watson, James, 14, 137
Waxman, Henry, xix–xxiii, 2–4
Webber, Chris, 128
Weissman, Charles, 72
Werth, Barry, 79
WFH. *See* World Federation of Hemophilia
WHIM syndrome, 161, 174–175
White, Ryan, 26
Whitesides, George, 31
Whitworth, Ralph, 110
Wilson, Jim, 48, 88, 130, 200
Wirth, Peter, 49, 112
Wood, Joan, 49
Woodcock, Janet, 167–168, 210
World Economic Forum, 112
World Federation of Hemophilia (WFH), 204
WuXi Biologics, 159
Wyzga, Mike, 49

X

X4 Pharmaceuticals, 174
X-linked adrenoleukodystrophy, 161

X-linked myotubular myopathy (XLMTM),
171–172
XLMTM. *See* X-linked myotubular
myopathy
Xue, James, 51

Y

Yamada, Tachi, 130, 200
Young, Mike, 102
Yu, Timothy, 210

Z

Zafgen, 173
Zamore, Phil, 84, 131–132
Zantac, 13
Zelig, Ze'ev, 63
Zerhouni, Elias, 18, 111–112, 114, 128
Zimran, Ari, 63
Zolgensma, 170–171, 203
Zynteglo, 125